Bullous pemphigoid burden of disease, management and unmet therapeutic needs

V P Werth; D F Murrell; P Joly; M Ardeleanu; V Hultsch

doi:10.1111/jdv.20313

Bullous pemphigoid burden of disease, management and unmet therapeutic needs

J Eur Acad Dermatol Venereol. 2024 Sep 19. doi: 10.1111/jdv.20313. Online ahead of print.

Authors

V P Werth^{1

2}, D F Murrell³, P Joly⁴, M Ardeleanu⁵, V Hultsch⁶

Affiliations

¹ Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
² Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
³ St George Hospital, University of New South Wales, Sydney, New South Wales, Australia.
⁴ Rouen University Hospital and INSERM 1234, Normandy University, Rouen, France.
⁵ Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.
⁶ Sanofi, Cambridge, Massachusetts, USA.

PMID: 39297242
DOI: 10.1111/jdv.20313

Abstract

Bullous pemphigoid (BP) is an autoimmune blistering disease that can have a profound negative impact on quality of life. BP most often affects the elderly, a population with a high medical burden and special safety concerns. In this review, we outline the BP disease course, diagnosis, epidemiology and comorbidities, and describe tools commonly used to assess BP disease activity and severity and the impact of BP on health-related quality of life. We also outline biologic treatments currently under investigation for the treatment of BP and highlight the importance of considering safety when treating elderly patients.

© 2024 Regeneron Pharmaceuticals. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Publication types

Review

Abstract

Publication types

Grants and funding